دورية أكاديمية
أعرض في EDS

Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors.

التفاصيل البيبلوغرافية
العنوان: Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors.
المؤلفون: Ciron C; Xenothera, Nantes, France., Morice P; Xenothera, Nantes, France., Rousse J; Xenothera, Nantes, France., Roy P; CRIP, Oniris, INRAE, Nantes, France., Royer PJ; Xenothera, Nantes, France., Gauthier O; CRIP, Oniris, INRAE, Nantes, France., Brouard S; Nantes Université, Inserm, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France., Duvaux O; Xenothera, Nantes, France., Bassissi F; Xenothera, Nantes, France., Vanhove B; Xenothera, Nantes, France.
المصدر: JCI insight [JCI Insight] 2024 Feb 08; Vol. 9 (3). Date of Electronic Publication: 2024 Feb 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]-
مواضيع طبية MeSH: Immune Checkpoint Inhibitors* , Melanoma*/therapy, Humans ; Rabbits ; Animals ; Mice ; Swine ; Mice, Nude ; Immunization ; Cell Line, Tumor ; Antibodies, Neoplasm/pharmacology
مستخلص: Heterologous polyclonal antibodies (pAb) were shown to possess oncolytic properties a century ago with reported clinical responses. More recent preclinical models confirmed pAb efficacy, though their ability to tackle complex target antigens reduces susceptibility to tumor escape. Owing to the recent availability of glyco-humanized pAb (GH-pAb) with acceptable clinical toxicology profile, we revisited use of pAb in oncology and highlighted their therapeutic potential against multiple cancer types. Murine antitumor pAb were generated after repeated immunization of rabbits with murine tumor cell lines from hepatocarcinoma, melanoma, and colorectal cancers. Antitumor pAb recognized and showed cytotoxicity against their targets without cross-reactivity with healthy tissues. In vivo, pAb are effective alone; moreover, these pAb synergize with immune checkpoint inhibitors like anti-PD-L1 in several cancer models. They elicited an antitumor host immune response and prevented metastases. The anticancer activity of pAb was also confirmed in xenografted NMRI nude mice using GH-pAb produced by repeated immunization of pigs with human tumor cell lines. In conclusion, the availability of bioengineered GH-pAb allows for revisiting of passive immunotherapy with oncolytic pAb to fight against solid tumor and cancer metastasis.
References: J Exp Med. 2013 Feb 11;210(2):257-68. (PMID: 23382542)
MAbs. 2021 Jan-Dec;13(1):1980942. (PMID: 34850665)
Immunol Res. 2012 Dec;54(1-3):247-53. (PMID: 22477527)
Int J Biol Sci. 2018 Sep 7;14(12):1621-1629. (PMID: 30416376)
Nat Med. 2015 Aug;21(8):914-921. (PMID: 26193344)
Toxicol Pathol. 2001 Mar-Apr;29(2):208-23. (PMID: 11421488)
Transplantation. 2005 Jul 27;80(2):279-81. (PMID: 16041276)
Br J Cancer. 1972 Jun;26(3):141-53. (PMID: 4114812)
J Immunother Cancer. 2019 Aug 14;7(1):217. (PMID: 31412943)
Cell Mol Immunol. 2020 May;17(5):451-461. (PMID: 32313210)
J Immunol Methods. 2020 Mar;478:112720. (PMID: 31812660)
Nat Rev Clin Oncol. 2021 Jun;18(6):327-344. (PMID: 33558752)
J Vis Exp. 2021 Oct 25;(176):. (PMID: 34747398)
Int J Mol Sci. 2021 May 26;22(11):. (PMID: 34073188)
Nat Med. 2000 Apr;6(4):443-6. (PMID: 10742152)
Immunol Res. 2014 Aug;59(1-3):203-10. (PMID: 24906530)
Immunol Rev. 1994 Oct;141:31-58. (PMID: 7868156)
Diabetologia. 2016 Jun;59(6):1153-61. (PMID: 27053235)
Sci Rep. 2020 Oct 28;10(1):18439. (PMID: 33116156)
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0123721. (PMID: 34181475)
Immunol Rev. 1994 Oct;141:169-90. (PMID: 7532618)
Diabetes. 2017 Apr;66(4):987-993. (PMID: 28082457)
J Immunol. 2011 Mar 15;186(6):3762-9. (PMID: 21296976)
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80. (PMID: 20160101)
Front Immunol. 2023 Feb 16;14:1137629. (PMID: 36875084)
Sci Rep. 2018 Oct 30;8(1):16008. (PMID: 30375476)
Eur J Cancer. 2014 Aug;50(12):2152-61. (PMID: 24915776)
J Cell Biochem. 2005 Oct 1;96(2):305-13. (PMID: 16052504)
Cancer Immunol Immunother. 2006 Aug;55(8):973-80. (PMID: 16151805)
Wiley Interdiscip Rev Membr Transp Signal. 2012 Mar;1(2):211-220. (PMID: 22662310)
Cancer Res. 1987 Aug 15;47(16):4293-5. (PMID: 2440563)
PLoS One. 2014 Mar 14;9(3):e88830. (PMID: 24633367)
J Clin Invest. 2015 Dec;125(12):4655-65. (PMID: 26551683)
Brain Res Rev. 2011 Jun 24;67(1-2):252-9. (PMID: 21356243)
Front Cell Dev Biol. 2021 Jul 08;9:689727. (PMID: 34307367)
Mol Oncol. 2014 Sep 12;8(6):1084-94. (PMID: 24913799)
Biomed J. 2019 Oct;42(5):299-306. (PMID: 31783990)
Transplantation. 2001 Feb 15;71(3):460-8. (PMID: 11233911)
Brain Res. 2010 Apr 22;1326:184-92. (PMID: 20193665)
Eur J Immunol. 2021 Jun;51(6):1412-1422. (PMID: 33576494)
Allergy Asthma Clin Immunol. 2017 Feb 23;13:13. (PMID: 28250777)
N Engl J Med. 2005 Feb 24;352(8):786-92. (PMID: 15728811)
J Oncol. 2019 Feb 28;2019:4508794. (PMID: 30941175)
Curr Opin Pharmacol. 2018 Aug;41:114-121. (PMID: 29883853)
Sci Rep. 2014 May 15;4:4984. (PMID: 24828460)
MAbs. 2017 Jul;9(5):774-780. (PMID: 28557665)
J Biomed Sci. 2017 Apr 4;24(1):26. (PMID: 28376884)
Adv Cancer Res. 1977;25:323-88. (PMID: 326003)
BioDrugs. 2009;23(5):289-304. (PMID: 19754219)
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11751-6. (PMID: 9751737)
J Clin Invest. 2019 Oct 1;129(10):4151-4164. (PMID: 31449054)
Xenotransplantation. 2016 Jul;23(4):279-92. (PMID: 27373998)
Sci Rep. 2020 Dec 18;10(1):22292. (PMID: 33339858)
J Immunol. 2013 Jan 1;190(1):231-9. (PMID: 23225880)
Trials. 2021 Mar 9;22(1):199. (PMID: 33750432)
Antibodies (Basel). 2020 Aug 18;9(3):. (PMID: 32824645)
Cancer Res. 2010 Apr 15;70(8):3209-17. (PMID: 20354182)
Nat Rev Drug Discov. 2019 Aug;18(8):585-608. (PMID: 31175342)
Oncotarget. 2016 Oct 11;7(41):67061-67070. (PMID: 27563813)
J Exp Med. 2017 Apr 3;214(4):895-904. (PMID: 28302645)
فهرسة مساهمة: Keywords: Cancer immunotherapy; Oncology
المشرفين على المادة: 0 (Immune Checkpoint Inhibitors)
0 (Antibodies, Neoplasm)
تواريخ الأحداث: Date Created: 20231212 Date Completed: 20240209 Latest Revision: 20240329
رمز التحديث: 20240329
مُعرف محوري في PubMed: PMC10967460
DOI: 10.1172/jci.insight.166231
PMID: 38085594
قاعدة البيانات: MEDLINE
الوصف
تدمد:2379-3708
DOI:10.1172/jci.insight.166231